A bioengineered naturally derived sustainable biocide for breaking down organi...
A bioengineered naturally derived sustainable biocide for breaking down organic biofilms formed by drug resistant bacteria.
Aequor's ABD (Aequor Biofilm Dispersant) represents a significant leap forward in the arms race between modern medicine and drug-resistant bacteria. The biofilm is the first line of defence for these drug-resistant microorganisms,...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PROTEIN-BIOFILM
Characterization of protein dependent biofilms by Staphyloco...
45K€
Cerrado
BACtheWINNER
Bacteriocins from interbacterial warfare as antibiotic alter...
3M€
Cerrado
TuniPeps
Discovering a new family of hypermodified antimicrobial pept...
189K€
Cerrado
CTQ2014-60250-R
DESARROLLO DE PROCESOS ENZIMATICOS PARA SU EMPLEO EN LA BIOP...
157K€
Cerrado
BIOPTAL
Bioactive Octopus peptides with potential for aquaculture
161K€
Cerrado
SAF2013-48971-C2-2-R
APLICACIONES BIOMEDICAS DE AS-48: UNA PROTEINA CON AMPLIO ES...
157K€
Cerrado
Información proyecto ABD
Duración del proyecto: 4 meses
Fecha Inicio: 2016-12-07
Fecha Fin: 2017-04-30
Líder del proyecto
GOLDSMITHS' COLLEGE
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Aequor's ABD (Aequor Biofilm Dispersant) represents a significant leap forward in the arms race between modern medicine and drug-resistant bacteria. The biofilm is the first line of defence for these drug-resistant microorganisms, a polymer-like structure of proteins and secretions that protects the colony from virtually everything but burning or scraping it away.
ABD does away with this problem in dramatic fashion. A natural biocidal agent derived from marine microorganisms, ABD is devastating for bacterial contamination, but gentle enough to be used as a supplement for antibiotic treatments. It is 99.99% effective at removing existing biofilms, prevents 99.99% of new biofilms from forming, and inhibits the growth of new bacterial colonies by over 92%. Lonza Group AG has verified this stellar performance in-vitro.
Aequor intends to use the funds from the SME instrument to study the EU and global market for biocides further, and to dig deeper into markets for antibiotic supplements. Further it will carry out growth projections and examine the process for clinical trials in-depth.